A preliminary clinical study has demonstrated that the experimental drug tofersen may be effective in the treatment of a genetic form of ALS.
The National Institute for Health and Care Excellence (NICE) has recommended the use of four out of six disease-modifying therapies in relapsing–remitting multiple sclerosis.
According to a recent study, an anti-inflammatory drug given to patients in the early stages of a stroke could reduce harmful inflammation.
The enzyme asparagine endopeptidase could be a key mediator in the cleavage and aggregation of alpha-synuclein in Parkinson’s disease.
This study aimed to assess the attitudes and opinions of clinicians practicing in psychiatry toward pharmacogenomic testing, and in so doing elicits possible barriers and risks to employ this technology in patient care.
AAN17: Phase III study reports the positive effects of an “old” drug for the treatment of advanced Parkinson’s disease
Study participants receiving apomorphine also gave their treatment higher effectiveness scores than those who received the placebo.
The authors assess the value of utilizing pharmacogenetic information to improve antidepressant drug therapy in BPD patients.
Identifying genetic loci affecting antidepressant drug response in depression using drug–gene interaction models
In this review, the researchers discuss the methodological challenges and limitations of the studies that have been conducted on this topic to date (e.g., ‘treated-only design’, statistical power) and discuss how specifically drug–gene interaction models can be used to be better able to identify genetic variants associated with antidepressant drug response in depression.
This report discusses how drug repurposing can be harnessed to identify new therapeutic opportunities, where such efforts are already yielding promising results, and which ones must be considered failures.
Researchers demonstrate that the drug laquinimod may reduce prevalence of multiple sclerosis and slow progression of the disease in animal models.